1. 1 From Cause to Movement Shaping a World Without Alzheimer’s Through Advocacy, Volunteerism, Referral and Science Ian Kremer, Esq. Advocacy & Outreach Director Alzheimer’s Association® National Capital Area Chapter

2. 2 Learning Objectives  Our nation no longer has the option to accept Alzheimer’s and related disorders  Health care professionals, consumers and the Alzheimer’s Association must collaborate to advance diagnosis, care and research  Our actions will accelerate science and change the trajectory of the Alzheimer epidemic

3. 3 From Cause to Movement  Necessity & Opportunity  National Priority  Transformative Change

4. 4 Alzheimer’s: the Silent Epidemic  5.4 million Americans have Alzheimer’s (including 200,000 with young onset)  14.9 million unpaid family caregivers  Alzheimer’s is the only top-10 cause of death without a known way to prevent, slow or cure  Unless we change the trajectory,13-16 million Americans will have Alzheimer’s by mid-century

5. 5 Source: Hebert et al. (2001). Alzheimer Disease Associated Disorders, 15(4), 169-173. Estimated Number of New Alzheimer’s Cases (In Thousands)

6. 6 Alzheimer’s Disease Impact on Baby Boomers  One in six women and one in ten men age 55 and older can expect to develop Alzheimer’s disease.  One in eight people over age 65 have Alzheimer’s  One in two people over age 85 have Alzheimer’s

7. 7 News You Can (and Must) Use  Early Detection, Proper Diagnosis & Documentation  Sharing the News with Patient/Family  Referral to Community Resources  Participation in Clinical Trials  Collaboration with Alzheimer’s Association  Advocacy

8. 8 Alzheimer’s Disease: Course, Prevention, Treatment Strategies Disease Progression No Disease No Symptoms Early Brain ChangesNoSymptoms AD Brain ChangesMildSymptoms Mild, Moderate, or SevereImpairment NormalAD Pre- symptomatic AD Mild Cognitive Impairment SecondaryPreventionTreatmentPrimaryPrevention ClinicalState BrainPathologicState ClinicalState Intervention

9. 9 Treatment Outcomes in Alzheimer’s Disease Time Functional ability Slowing of disease progression Treatment Symptomatic benefit Maintenance of function Cure Natural Progression

10. 10

11. 11 Alzheimer’s Association TrialMatch™  Free, easy to use service  Preview over 100 studies related to MCI, Alzheimer’s and related disorders  Match specific profiles of patient diagnosis, clinical history and location with study criteria

12. 12 Medical Community Collaboration  Purple Envelope Project  Physician Outreach Project  Jane.Priest@alz.org or 703-766-9018 Jane.Priest@alz.org

13. 13 Advocacy Goals  Alzheimer’s Breakthrough Act  HOPE for Alzheimer’s Act (Health Outcomes, Planning & Education)  National Alzheimer’s Project Act (implementation input napa.alz.org)

14. 14 Our Vision: A World Without Alzheimer’s www.alz.org/nca 1.800.272.3900